- 专利标题: ANTIBODY BINDING TO FCRN FOR TREATING AUTOIMMUNE DISEASES
-
申请号: EP15785500申请日: 2015-04-30
-
公开(公告)号: EP3137504A4公开(公告)日: 2018-02-28
- 发明人: KIM SUNG WUK , PARK SEUNG KOOK , JEONG JAE KAP , AHN HYEA KYUNG , KIM MIN SUN , KIM EUN SUN , YONG HAE-YOUNG , SHIN DONGOK , SONG YEON JUNG , YOO TAE HYOUNG
- 申请人: HANALL BIOPHARMA CO LTD
- 专利权人: HANALL BIOPHARMA CO LTD
- 当前专利权人: HANALL BIOPHARMA CO LTD
- 优先权: US201461986742 2014-04-30
- 主分类号: C07K16/46
- IPC分类号: C07K16/46 ; A61K39/395 ; A61P37/00 ; C07K16/18 ; C12N15/13 ; C12N15/63 ; G01N33/53
摘要:
The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
信息查询